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SIGNIFICANCE
Erythrodermic mycosis fungoides and Sézary syndrome 
share clinical and histological features, making it difficult to 
distinguish these diseases. It has been discussed previous­
ly whether erythrodermic mycosis fungoides and Sézary 
syndrome are different stages of the same disease. How­
ever, differences in treatment and prognoses indicate that 
the diseases should be considered separately. MicroRNAs 
are small sequences of RNA, which have the potential to 
discriminate clinically similar diseases. This study showed 
that 27 microRNAs discriminated erythrodermic mycosis 
fungoides from Sézary syndrome. These data support the 
perception of erythrodermic mycosis fungoides and Sézary 
syndrome as different diseases.
It is difficult to distinguish erythrodermic mycosis 
fungoides from Sézary syndrome due to their similar 
clinical and histological features. The main purpose of 
this study was to investigate whether microRNA ex-
pression profiles in lesional skin could discriminate pa-
tients with erythrodermic mycosis fungoides from those 
with Sézary syndrome. A further aim was to assess 
whether the microRNA expression profiles in erythro-
dermic mycosis fungoides skin was more comparable 
to microRNA expression profiles of Sézary syndrome 
or early-stage mycosis fungoides. RNA was extracted 
from diagnostic skin biopsies, followed by quantita-
tive reverse transcription polymerase chain reaction 
analysis of 383 microRNAs. Twenty-seven microRNAs 
were significantly differentially expressed between 
erythro dermic mycosis fungoides and Sézary syndro-
me. More over, erythrodermic mycosis fungoides sho-
wed microRNA features overlapping with Sézary syn-
drome and early-stage mycosis fungoides, although 
hierarchical cluster analysis co-clustered erythro-
dermic mycosis fungoides with early-stage mycosis 
fungoides rather than with Sézary syndrome. These 
findings underscore that erythrodermic mycosis 
fungoides and Sézary syndrome are different diseases.
Key words: mycosis fungoides, Sézary syndrome, cutaneous T­
cell lymphoma, microRNA.
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Cutaneous T-cell lymphoma (CTCL) is a group of rare heterogeneous lymphoproliferative disorders prima-
rily confined to the skin. The most prevalent clinical form 
of CTCL is mycosis fungoides (MF) (1, 2). Early-stage 
MF comprises patch and plaque skin lesions, whereas 
advanced stages involve skin tumours and erythrodermic 
MF (eMF) (3, 4). eMF and the more aggressive leukae-
mic variant, Sézary syndrome (SS), are characterized by 
chronic erythroderma with ≥ 80% skin involvement (4). 
eMF and SS are difficult to distinguish because of their 
similar clinical features, with erythroderma and lymph-
adenopathy combined with symptoms such as pruritus, 
skin burning, and chills (5). However, eMF sometimes 
progresses through patch- and/or plaque-stage disease 
and has various levels of blood involvement, whereas SS 
usually presents with erythroderma and significant blood 
involvement (6, 7). Controversies still exist regarding 
whether MF and SS are distinct diseases or different 
manifestations of a single disease (8, 9), which has led 
to substantial discussions about the distinction between 
eMF and SS (6, 9, 10). Discrimination between SS and 
eMF is essential due to differences in treatment recom-
mendations and prognosis (7, 11, 12).
MicroRNAs (miRNAs) may have the potential to 
discriminate between SS and eMF. miRNAs are short 
non-coding RNA molecules that regulate gene expres-
sion by modulating translation of messenger RNA (13). 
Thus, miRNAs are involved in important biological 
functions, and altered regulation of miRNAs plays a key 
role in cancer development, progression and metastasis 
(14). Many miRNAs are differentially expressed in 
CTCL compared with normal skin (15–17). They have 
been proposed to discriminate CTCL from benign skin 
diseases as a diagnostic marker (18–20), and a prognostic 
3-miRNA classifier was developed recently for patients 
diagnosed with early-stage MF (21). Moreover, single 
miRNAs (e.g. miR-155) may have essential regulatory 
functions in CTCL (22, 23), and a drug targeting miR-
155, cobomarsen, was developed recently and tested in 
a clinical trial with promising outcomes (24). 
This study examined the miRNA expression profiles 
of diagnostic lesional skin biopsies from early-stage MF, 
eMF, and SS, with the aim of: (i) examining whether 
a distinct miRNA expression profile can discriminate 
eMF from SS; and (ii) addressing whether the miRNA 
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signature in eMF is more similar to the signature in SS 
than to the miRNA profile in early-stage MF skin.
METHODS
Patients
Formalin-fixed paraffin-embedded skin biopsies, used for first-
time diagnosis of early-stage MF, eMF and SS were collected. 
The study included 15 patients with early-stage MF, 14 with eMF 
and 11 with SS diagnosed in the period between 1981 and 2013. 
Patients with early-stage MF (stages IA–IB) were diagnosed 
and grouped in accordance with the International Society for 
Cutaneous Lymphomas/European Organization of Research and 
Treatment of Cancer (ISCL/EORTC) recommendations from 2007 
(4). Early-stage patients have also been included in a previous 
study by Lindahl et al. (21). eMF and SS were categorized in ac-
cordance with the clinical guidelines at the time of diagnosis. A 
diagnosis of SS required erythroderma, compatible histology, and 
blood involvement of at least 5% of Sézary cells (25, 26). Relevant 
clinical variables, such as sex, age, and treatment at the time of 
diagnosis, were obtained from the patient files.
The study was approved by the local ethics committee (1-10-
72-91-13) and the Danish Data Protection Agency (Datatilsynet 
1-16-02-478-15). 
RNA extraction and quantitative reverse transcription PCR (qRT-
PCR) profiling 
Biopsies were cut into 10-µm tissue sections, and RNA was 
extracted using the RecoverAll Total Nucleic Acid Isolation Kit 
(ThermoFisher Scientific/Applied Biosystems, Waltham, MA, 
USA) according to the manufacturer’s guidelines. Total RNA 
quantity and quality controls were performed using a NanoD-
rop-1000 spectrophotometer. The extracted RNA was used for 
qRT-PCR-based miRNA profiling covering 383 human miRNAs, 
as described previously (21).
Statistical analysis
The miRNAs with signals close to or below the detection limit 
(Ct>37) in most or all samples were excluded from further analy-
ses, leaving 264 specific miRNAs for further analyses. Data were 
normalized by a global mean approach. 
Data were visualized by heatmaps and unsupervised hierarchical 
clustering in Qlucore Omics Explorer v.3.4 (Qlucore AB, Lund, 
Sweden). Analysis of variance (ANOVA) was used to detect dif-
ferentially expressed miRNAs between the 3 groups. Differences 
in miRNA expression levels were considered significant at > 1.5 
fold-change (FC) and p-value < 0.05. Adjustment for multiple 
testing was carried out by estimation of the false discovery rate 
(Q value). Target prediction and pathway analysis were performed 
by applying DIANA-miRPath v.3.0 (27).
RESULTS
Patient characteristics
Patient characteristics are listed in Table I. A total of 
40 patients were identified; 15 with early-stage MF, 14 
with eMF and 11 with SS. Median age at diagnosis was 
66 years (range 47–88 years) in patients with early-stage 
MF, 76 years (range 51–94 years) in patients with eMF, 
and 74 years (range 55–86 years) in patients with SS 
and did not differ between the patient groups (1-way 
analysis of variance (ANOVA), p = 0.12). Eleven patients 
with early-stage MF, 6 with eMF, and 3 with SS did not 
receive CTCL-directed therapy at the time of diagnosis. 
Topical treatment was assigned to 4 patients with early-
stage MF, 8 with eMF, and 5 with SS. Systemic therapy 
was given to 3 patients with eMF, 3 with SS, and none 
of the early-stage MF patients at the time of diagnosis.
miRNA expression profile can discriminate erythrodermic 
mycosis fungoides from Sézary syndrome
The miRNA expression profile was distinctly different 
in skin biopsies from patients with eMF compared with 
patients with SS (Fig. 1). Twenty-seven miRNAs with 
strong (FC>1.5) and significantly different expression in 
eMF vs. SS (Fig. 1) were identified. Fourteen miRNAs 
Table I. Clinical characteristics
Pat. No. Sex
Age at biopsy 
(years)
Treatment at time 
of diagnosis Stage T­stage
Mycosis fungoides T1 + T2
1 F 70 No treatment IB 2
2 M 66 No treatment IA 1
3 F 88 No treatment IB 2
4 M 66 Ultraviolet B IA 1
5 M 71 No treatment IB 2
6 M 60 Topical steroid IA 1
7 M 67 No treatment IA 1
8 F 58 Topical steroid IA 1
9 M 71 No treatment IB 2
10 F 72 No treatment IB 2
11 M 85 Ultraviolet B IB 2
12 M 50 No treatment IB 2
13 F 51 No treatment IB 2
14 F 65 No treatment IB 2
15 M 47 No treatment IA 1
Mycosis fungoides T4
16 F 82 Oral steroid
Topical steroid
IIIA 4
17 M 79 Topical steroid IIIA 4
18 M 51 Etretinate
Topical steroid
IIIA 4
19 F 83 Topical steroid IIIA 4
20 M 68 No treatment IIIA 4
21 M 74 Topical steroid IIIA 4
22 M 84 Topical steroid IIIA 4
23 M 76 Methotrexate
Topical steroid
IIIA 4
24 M 60 No treatment IIIA 4
25 M 75 No treatment IIIA 4
26 F 94 No treatment IIIA 4
27 M 69 No treatment IIIA 4
28 M 80 No treatment IIIA 4
29 M 65 Topical steroid IIIA 4
Sézary syndrome
30 M 55 Topical steroid 4
31 F 85 No treatment 4
32 M 75 No treatment 4
33 M 64 Topical steroid 4
34 M 65 Topical steroid 4
35 F 59 Topical steroid 4
36 F 83 No treatment 4
37 F 80 Topical steroid 4
38 M 80 Alemtuzumab 4
39 M 74 Oral steroid 4
  40 M 64 Oral steroid
Ciclosporin
4
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were expressed at lower levels, and 13 were expressed 
at higher levels in eMF compared with in SS. Notably, 
miRNAs, such as miR-106b, miR-142, miR-155 and 
miR-21, which may play an important role in progression 
of CTCL (21, 22, 28, 29) had significantly lower expres-
sion levels in eMF compared with in SS. Unsupervised 
hierarchical clustering showed that the 27 differentially 
expressed miRNAs clearly separated eMF from SS (Fig. 
1). Three patients with SS clustered with the eMF pa-
tients. Of note, 2 of these patients (patients 39 and 40) 
were treated with oral corticosteroids (daily dose 25 and 
15 mg, respectively), whereas none of the other patients 
with SS received this treatment. 
miRNA expression in erythrodermic mycosis fungoides 
(MF) and Sézary syndrome compared with early-stage MF 
Next, miRNA expression in eMF and SS were compared 
with that in patients with early-stage MF. Twenty-eight 
significantly differentially expressed miRNAs were 
identified in skin lesions from eMF compared with 
early-stage MF (p < 0.05, FC > 1.5) (Fig. 2a). Two-way 
unsupervised hierarchical clustering based on the 28 dif-
ferentially expressed miRNAs discriminated eMF from 
early-stage MF, albeit with some overlap. Patients 16, 20, 
22, 25 and 26 diagnosed with eMF sub-clustered with 4 
patients with early-stage MF before clustering with the 
rest of the patients with eMF. This subdivision of the 
eMF disease group did not depend on disease stage (IA/
IB) of the early-stage MF group, treatment at the time 
of diagnosis, or sex. 
The miRNA expression in SS also differed from the 
expression pattern observed in early-stage MF. Thirty-
four significantly differentially expressed miRNAs were 
identified (Fig. 2b, p < 0.05, > 1.5 FC, Q < 0.30), which 
separated the 2 disease entities, as illustrated by the 
unsupervised hierarchical clustering (Fig. 2b). How-
ever, the 2 patients with SS who were treated with oral 
corticosteroids (patients 39 and 40) clustered with the 
patients with early-stage MF. Thus, oral corticosteroid-
induced skin improvement seems to induce changes in 
the miRNA expression pattern toward what is observed 
in early-stage MF. 
Eleven miRNAs separated both eMF and SS from 
early-stage MF. Of these 11 miRNAs, 4 were expressed at 
significantly higher levels in SS and eMF vs. early-stage 
MF (miR-22-3p, miR-199a-3p, miR-199a-5p, miR-199b-
5p), and 7 were expressed at significantly lower levels 
(miR-27b-5p, miR-328-3p, miR-342-3p, miR-433-3p, 
miR-483-3p, miR-484, and miR-663a). 
Differentially expressed miRNAs between all patient 
groups 
Fifty-four miRNAs were significantly differentially ex-
pressed between all patient groups (p < 0.05, Q = 0.24). 
In the heatmap and unsupervised hierarchical clustering 
based on these 54 miRNAs, the 3 disease entities, eMF, 
SS and early-stage MF, separated into distinct clusters, 
although with some overlap (Fig. 3). Interestingly, eMF 
displays miRNA features overlapping with both those 
of SS and of early-stage MF, although the hierarchical 
cluster analysis suggests eMF co-clustering with early-
stage MF rather than with SS.
Differences in predicted miRNA-induced downstream 
pathway activation 
Differences in the miRNA expression profile between 
eMF and SS may reflect differences in downstream 
pathway activation between eMF and SS. Therefore, 
we performed a pathway analysis using DIANA-tools 
and miRPath v3.0 based on the 27 miRNAs that were 
significantly differentially expressed between eMF and 
SS. Pathways of particular interest in CTCL are shown 
in Table II, indicating possible involvement of signalling 
Fig. 1. Heatmap of significantly differential expressed microRNAs 
between erythrodermic mycosis fungoides (eMF) and Sézary 
syndrome (SS). Heatmap and unsupervised 2­way hierarchical clustering 
based on the 27 microRNAs with strong (fold-change > 1.5) and significantly 
(p < 0.05) differential expression between eMF and SS.
A
ct
aD
V
A
ct
aD
V
A
d
v
a
n
c
e
s 
in
 d
e
rm
a
to
lo
g
y
 a
n
d
 v
e
n
e
re
o
lo
g
y
A
c
ta
 D
e
rm
a
to
-V
e
n
e
re
o
lo
g
ic
a
1151MicroRNAs in erythrodermic mycosis fungoides and Sézary syndrome
Acta Derm Venereol 2019
pathways associated with cancer (i.e. mitogen-activated 
protein kinase (MAPK), tumour necrosis factor (TNF), 
T-cell receptors, mechanistic target of rapamycin kinase 
(mTOR), and phosphatidylinositol 3-kinase-serine/threo-
nine kinase (PI3K-Akt).
DISCUSSION 
This study provides evidence that the miRNA expression 
profile in lesional skin can discriminate eMF from SS. 
Twenty-seven miRNAs separated the 2 disease entities 
and were significantly differentially expressed between 
eMF and SS. Moreover, the miRNA expression profile of 
eMF differs from both SS and early-stage MF; however, 
hierarchical clustering showed that eMF co-clustered 
with early-stage rather than SS.
It is essential to discriminate eMF from SS due to diffe-
rences in treatment recommendation and prognosis, with 
patients with SS in stage B2 having significantly higher 
mortality rates (4, 30). Several studies have indicated that 
miRNAs are involved in the pathogenesis and disease 
progression and serve as markers of diagnosis and prog-
nosis in CTCL (18–21, 23, 29, 31). In this study, 19 out 
of the 27 significantly differentially expressed miRNAs 
between eMF and SS have previously been linked to 
CTCL (15, 16, 18, 21, 28, 32). In particular, miR-106b, 
miR-155 and miR-21 showed significantly higher expres-
sion levels in SS and have previously been associated 
with progression of CTCL: miR-106b was included in the 
prognostic miRNA classifier developed for early-stage 
CTCL (21) and miR-21 is induced by IL15 and STAT5, 
which are important regulators of proliferation and cell 
survival in CTCL (29, 33). Most widely investigated is 
the STAT5 regulated miR-155 (22). There is a higher ex-
pression of miR-155 in SS compared with MF (34). Ex-
pression levels of miR-155 increases with MF stage (35) 
and a recent identified diagnostic- and prognostic classier 
includes miR-155 expression levels (36). Due to its role 
in constitutive activation of important intracellular sig-
nalling pathways, and proliferation of malignant T cells, 
miR-155 is a promising therapeutic target in CTCL (22, 
37). Another potential miRNA target in CTCL is miR-214 
Fig. 2. Heatmaps of significantly differential expressed microRNAs 
when comparing erythrodermic mycosis fungoides (eMF) vs. early-
stage MF and Sézary syndrome (SS) vs. early-stage MF. Heatmap and 
unsupervised 2-way hierarchical clustering based on significantly regulated 
microRNAs. (A) Shows the 29 microRNAs that differ the most between eMF 
and early­stage disease. (B) Represents the 36 microRNAs that differ the 
most between SS and early­stage disease.
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(38, 39). In addition, we found higher expression levels 
of miR-181a and miR-146a in the advanced stages of 
CTCL. Manso et al. showed a similar expression pattern 
and hypothesized miR-181a and miR-146a to play a role 
in disease progression (40).
Accordingly, the identified miRNA signature may play 
an important role in the pathogenesis and progression 
of CTCL. Moreover, the downstream signalling of the 
discriminative miRNAs between eMF and SS revealed 
signalling pathways fundamental in CTCL, which is 
indicative of the importance of these miRNAs (Table II).
Taken together, the present findings strongly indicate 
that miRNAs are important players in the CTCL patho-
genesis and that the miRNA expression profile reflects 
the stage, aggressiveness, and disease entity of CTCL. 
The study is limited by its retrospective design, and 
a prospective validation of the findings would have 
been preferred. Moreover, despite the rarity of CTCL, 
we would have preferred to include a larger number of 
patients. 
The Danish registry system enabled identification of 
the specific biopsy used for the first diagnosis of eMF, SS, 
and early-stage MF and precise linkage to clinical cha-
racteristics of each individual patient, which strengthens 
the study. The technical and biological robustness of 
miRNAs in FFPE-preserved skin biopsies is a further 
strength of the study. 
In conclusion, the miRNA expression profile in di-
agnostic skin biopsies can discriminate eMF from SS 
despite clinical and histological similarities. These results 
emphasize that eMF and SS represent distinct disease 
entities based on the miRNA signature of skin. 
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